Drug intelligence / Profile preview

S233107

Development stage: Preclinical
Lead developer: Servier
Administration: Oral

Overview

S233107 is an investigational drug candidate currently in preclinical development by Servier and its subsidiary Symphogen. It is being developed for the treatment of developmental and epileptic encephalopathies (DEE), a group of rare and severe epilepsy syndromes characterized by both frequent seizures and developmental impairment. As of early 2026, the program is active in the company's development pipeline; however, specific details regarding its molecular target, mechanism of action, and therapeutic modality remain proprietary and have not been publicly disclosed.

Beyond the preview

Go deeper on S233107.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on S233107.

Explore the full profile